Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration

By afschroeder • December 9, 2025

Rosen LS, Ottensmeier C, Hawkins M, Naing A, Sonpavde G, Van Tine BA, Parkes EE, O'Cathail SM, Ji RR, Thomas M, Stacey A, Sasso MS, Rosen O. Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration. J Immunother Precis Oncol. 2025 Nov 25;8(4):263-275. doi: 10.36401/JIPO-25-18. PMID: 41358276; PMCID: PMC12681188.

Tags: Hematology/Oncology, immunotherapy, oncolytic immunotherapies, Publications, solid tumors, Tolerability, viral persistence

Screening for frailty and malnutrition in a multidisciplinary head and neck cancer program

Brauer ER, Lazaro S, Economou DR, Rapkin D, Wong DJ, St John MA. Screening for frailty and malnutrition in a multidisciplinary head and neck cancer[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study

Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen[...]